INTRODUCTION
Antibiotic resistance in Gram-negative bacteria is a major global cause of morbidity and mortality [1] . It has been identified as an urgent priority by the WHO, EU and US and UK Governments [2] [3] [4] [5] .
PPI use reduces gastric acidity, alters the gut microbiome [6] , and increases the risk of gastroenteritis by enabling ingested pathogens to survive passage through the stomach [7] . The protective effect of gastric acid is unrelated to antibiotic resistance, so it is possible that PPI use might encourage colonisation by resistant or sensitive bacteria, with subsequent risk of systemic infection? Very little research has been carried out to investigate this, particularly in UK hospital patients.
We carried out a retrospective case-control study of PPI exposure in hospital cases infected with extended-spectrum -lactamase producing Enterobacteriacae (ESBL ) compared with two demographically matched control groups. The first group were patients infected with extendedSpectrum -lactamase negative Enterobacteriacae (non-ESBL) and the second group were patients with no identified enterobacteriaceal infection matched by primary diagnosis (uninfected).
METHODS

STUDY COHORT
This study was carried out in Derriford Hospital, a 1000 bed university teaching hospital in South Results of the regression models were presented as odds ratio (OR) along with their 95% confidence intervals (CIs). A factor was considered statistically significant if the 95% CI of the corresponding OR did not contain 1. Whenever appropriate, a 5% level of significance was considered. Data analysis was performed using IBM SPSS Statistics 23 and STATA 14.
PATIENT INVOLVEMENT
No patients were involved in the design or implementation of the study, or writing up of results.
RESULTS
Characteristics of case and control patients are summarised in Table I . The median (IQR) time between admission and sample collection was 2 (11.3) days for ESBL cases and 1 (5.5) days for non-6 ESBL controls. This suggests that colonisation occurred prior to admission in most cases, rather than being hospital acquired. The median (IQR) duration of admission of uninfected controls was shorter than either of the infected groups at two (11) days versus 12 (20) days for cases and 9 (16) days for non-ESBL controls. The Charlson co-morbidity score for cases ranged from 0 to 12 and that of controls ranged from 0 to 14. This was not significantly different between cases and controls.
The results of exposure to gastric acid suppressants are summarised in Table II . 66 ESBL cases (59 on admission and 7 in the previous six months) were exposed to PPIs, compared with 34 (31 on admission, 3 in the previous six months) of the uninfected controls and 62 (55 on admission, 7 in the previous 6 months) of the non-ESBL controls. After multivariable analysis the OR (95% CI) for PPI exposure in cases compared to uninfected controls was found to be 3.37 (1.84 to 6.18). No significant difference was found for PPI exposure in ESBL cases and non ESBL controls.
6 ESBL cases were taking H2RA on admission, compared with 9 of the uninfected controls and 7 of the non-ESBL controls. 4 ESBL cases were taking antacids on admission, compared with 2 of the uninfected controls and 3 of the non-ESBL controls. No significant association was found between cases and either control group for H2RA or antacids.
DISCUSSION
We found that exposure to PPIs is a significant risk factor for infection with both ESBL producing and non-ESBL producing Enterobacteriacae. This is a novel and important finding, as PPIs are widely overused, antibiotic resistance is a major threat, and conventional control measures will require an unprecedented level of global cooperation [8, 9] . Increased transmission of susceptible organisms following reduction in gastric acidity is just as important as the effect on resistant ones, as treatment of subsequent infections will increase antibiotic consumption and drive development of resistance.
New antibiotic classes are unlikely to be a realistic solution. Resistance to these may already exist, as bacteria from ancient soil and mummified human remains contained genes coding for resistance thousands of years before antibiotics were developed [10, 11] . Global spread of resistance is inevitable, carried by healthy travellers [12] , and in foods from endemic areas [13] .
Gram-positive pathogens like meticillin-resistant Staphylococcus aureus are mainly spread by direct contact and are controllable with simple measures like hand washing and skin disinfection. Most transmission of Gram-negative bacteria is by ingestion, and bowel decolonisation is rarely successful.
They cause no symptoms when they first colonise the bowel. Unless the patient is actively screened they remain undetected until infection occurs in the future [14] .
Gastric acid is a vital host defence. It kills a wide range of bacteria, fungi and parasites. It acts synergistically with salivary nitrite, generating highly reactive nitrogen species at low pH. These are rapidly bactericidal, even killing acid tolerant organisms such as Clostridium difficile spores [15] .
Gastric acidity is reduced in the elderly, patients with pernicious anaemia, and patients taking PPIs.
The risk of infection with gastrointestinal pathogens is increased in all these groups [7] , our results suggest that the same mechanism encourages transmission of Enterobacteriacae.
PPIs are vital for treating peptic ulcers, gastroesophageal reflux and other serious conditions exacerbated by gastric acidity. Rapid efficacy and the misperception that they are free of significant adverse effects has encouraged overuse. Studies show that 40%-60% of acute hospital inpatients are prescribed a PPI, often outside evidence-based guidelines [16, 17] . In contrast to the complex strategies to control antimicrobial resistance recommended in the O'Neill report [8] , reducing inappropriate PPI use is a simple intervention which can be initiated by any prescriber or empowered patient. Like hand washing between patient contacts, it is simply good practice, but could have a disproportionate impact on the spread of bacterial resistance?
Strengths and limitations of study
The hypothesis that PPI use might be associated with ESBL infection was generated before collection or analysis of the data. When a positive association was found, a second control group of patients infected with non-ESBL bacteria was analysed. This study included 126 of 131 new cases of ESBL 8 infection over one year at a large UK teaching hospital. Derriford hospital provides general medical, surgical and obstetric care to an urban and rural population of 450,000, and specialist services such as neurosurgery, cardiothoracic surgery, bone marrow and solid organ transplantation to 1.7 million people. This varied case mix gives reassurance that the results are generalizable to similar centres.
Patients of all ages and from all specialties were included. We reviewed all available records, including casenotes, prescription charts and electronic records. Limitations of the study are that it is retrospective and single centre. We were unable to quantify any "over the counter" use of gastric acid suppressants; however PPIs were only available on prescription at the time so would not have affected our cohort. While every effort was made to match cases and controls, unrecognised comorbidities may have been present. Finally we chose six months prior to admission as a pragmatic cut off for review of prescriptions. PPI use more than six months prior to admission may well be a risk factor for acquisition of Enterobacteriacae, and further studies reviewing GP records for lifetime PPI use would more accurately define the risk.
Comparison with other studies
There is little published research on whether PPIs could be a risk factor for acquisition of Enterobacteriacae. A study in mice found that PPI treatment facilitated colonisation with Klebsiella pneumoniae and vancomycin-resistant enterococci [18] . Two studies of inpatients in Israel and the US incidentally found an association between gastric acid suppression and resistant
Enterobacteriacae, but they primarily focussed on other risk factors and did not comment specifically on PPIs [19, 20] . A cross-sectional study of adults registered with the Academic General Practice Network in Amsterdam in 2011 found an 8.6% prevalence of ESBL-producing enterobacteriaceae. Travel outside Europe, antibiotic use and use of gastric acid suppressants were all positively associated with carriage. Use of PPIs or H2RA had a multivariable odds ratio of 1.9
(95% CI 1.1 -3.3) [21] . Our study found a stronger association, perhaps because the hospital population has more comorbidity and is more intensively exposed to bacteria and antibiotics. A 9 cross-sectional study of patients routinely screened for ESBL producing Enterobacteriacae on admission to hospital in the Netherlands found that 8.5% of PPI users were carriers versus 2.9% of non-PPI users, (adjusted odds ratio 3.89, 95% CI 1.65 -9.19). Patients were screened within two days of admission thus excluding cross-infection within hospital, however they did not control for diagnosis or co-morbidities [22] . Søgaard et al in Denmark published a case-control study of community-onset ESBL E.coli UTI compared with non-ESBL E.coli UTI and population controls. They found a moderately increased risk of ESBL versus non-ESBL infection (OR 1.6, 95% CI 1.2 -2.0) and that most risk factors also applied for non-ESBL infection [23] . Finally, two studies have looked at the possible association between carbapenemase-producing Enterobacteriacae (CPE) and PPIs, with conflicting results. Weekly screening of 31,526 inpatients in Hong Kong found that concomitant use of antibiotics and PPIs prolonged the duration of CPE carriage [24] . A study of 747 inpatients in
Manchester was conducted during a CPE outbreak, with 70 CPE carriers identified. PPIs were not identified as a risk factor in this cohort, though they used PPI prescription in the 24 hours before the case finding exercise as a proxy measure of exposure. This would have underestimated any effect of previous PPI use [25] .
Clinical implications and future research
We found that PPIs are much more widely used than H2RA and antacids. Studies on gastroenteritis pathogens show a dose-response effect, with less potent agents conferring a lower risk. While the number of patients taking H2RA and antacids in our population was small, we did not detect any association with ESBL or non-ESBL infection. Future studies to confirm this would be useful, as substituting these for PPIs may be easier than stopping gastric acid suppression completely.
As part of a bundle of C.difficile control measures, the Pharmacy and Infection Prevention and 
CONCLUSIONS
We found a significant association between PPI exposure and infection with both ESBL and non-ESBL producing Enterobacteriacae. This is the first time this risk factor has been identified in a UK hospital population and the magnitude is greater than in previous community based studies. Applying evidence based guidelines on appropriate use of PPIs has the potential to reduce bacterial transmission without harming those patients who genuinely need such potent gastric acid suppression. 
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